ARS Pharmaceuticals, Inc. Common Stock (SPRY)

Price$8.18

Favorite Metrics

Price vs S&P 500 (26W)-31.80%

Price vs S&P 500 (4W)-9.20%

Market Capitalization$796.36M

P/E Ratio (Annual)102.30x

All Metrics

P/CF (Annual)60.39x

Book Value / Share (Quarterly)$1.15

P/TBV (Annual)11.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)299.68%

Cash Flow / Share (Quarterly)$-1.72

Price vs S&P 500 (YTD)-33.80%

Gross Margin (TTM)75.77%

Net Profit Margin (TTM)-203.25%

EPS (TTM)$-1.74

10-Day Avg Trading Volume1.28M

EPS Excl Extra (TTM)$-1.74

EPS (Annual)$-1.74

ROI (Annual)-81.33%

Gross Margin (Annual)76.72%

Cash / Share (Quarterly)$2.47

Revenue Growth QoQ (YoY)-67.56%

P/E Normalized (Annual)102.30x

ROA (Last FY)-52.28%

Revenue Growth TTM (YoY)-5.46%

EBITD / Share (TTM)$-1.70

ROE (5Y Avg)-42.32%

Operating Margin (TTM)-212.92%

Cash Flow / Share (Annual)$-1.72

P/B Ratio6.97x

P/B Ratio (Quarterly)10.08x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)10.10x

Net Interest Coverage (TTM)-64.94x

ROA (TTM)-51.09%

EV / EBITDA (TTM)101.78x

EPS Incl Extra (Annual)$-1.74

Current Ratio (Annual)7.28x

Quick Ratio (Quarterly)6.91x

3-Month Avg Trading Volume1.49M

52-Week Price Return-44.58%

EV / Free Cash Flow (Annual)65.84x

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)9.45x

Asset Turnover (Annual)0.26x

52-Week High$18.90

EPS Excl Extra (Annual)$-1.74

CapEx CAGR (5Y)-18.10%

26-Week Price Return-27.81%

Quick Ratio (Annual)6.91x

13-Week Price Return-29.53%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)7.28x

Enterprise Value$851.421

Asset Turnover (TTM)0.25x

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-203.35%

Cash / Share (Annual)$2.47

3-Month Return Std Dev55.54%

Net Income / Employee (TTM)$-1

ROE (Last FY)-149.92%

Net Interest Coverage (Annual)-14.93x

EPS Basic Excl Extra (Annual)$-1.74

Receivables Turnover (TTM)5.03x

Total Debt / Equity (Quarterly)0.84x

EPS Incl Extra (TTM)$-1.74

ROI (TTM)-78.24%

P/S Ratio (TTM)9.45x

Revenue / Share (Annual)$0.85

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-74.41%

Year-to-Date Return-31.16%

5-Day Price Return-3.02%

EPS Normalized (Annual)$-1.74

ROA (5Y Avg)-22.49%

Net Profit Margin (Annual)-203.25%

Month-to-Date Return-0.12%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-1.70

Operating Margin (Annual)-212.92%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-28.60%

LT Debt / Equity (Quarterly)0.84x

EPS Basic Excl Extra (TTM)$-1.74

P/TBV (Quarterly)11.54x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)3.01x

Pretax Margin (TTM)-203.35%

Book Value / Share (Annual)$1.15

Price vs S&P 500 (13W)-30.21%

Beta0.93x

P/FCF (Annual)61.33x

Revenue / Share (TTM)$0.85

ROE (TTM)-100.29%

52-Week Low$6.66

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.42

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SPRYARS Pharmaceuticals, Inc. Common Stock	9.45x	-5.46%	75.77%	—	$8.18
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

ARS Pharmaceuticals commercializes Neffy, a needle-free intranasal epinephrine treatment for Type 1 allergic reactions and anaphylaxis. The proprietary formulation combines epinephrine with an absorption enhancer to deliver efficacy comparable to injectable alternatives. Neffy is marketed globally under different trade names, including EURneffy in the European Union and United Kingdom.